Somatogen
Executive Summary
Recombinant human hemoglobin (rHb1.1) enters clinical trials in anesthetized surgical patients. The Phase I protocol for the blood substitute received approval of the institutional review board at the University of Utah. Baxter was the first company to enter clinical trials with a blood substitute, beginning Phase I trials of DCLHb in mid-July in victims of hemorrhagic shock.